Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Enliven Therapeutics, Inc. (NASDAQ:ELVN) has been assigned a consensus recommendation of “Moderate Buy” from the six ratings firms that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $41.20.

A number of analysts have recently issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Wednesday, October 8th. HC Wainwright lifted their price objective on shares of Enliven Therapeutics from $40.00 to $48.00 and gave the company a “buy” rating in a research note on Wednesday, July 2nd.

Enliven Therapeutics Stock Down 1.6%

ELVN opened at $21.41 on Friday. The firm has a market capitalization of $1.27 billion, a P/E ratio of -10.71 and a beta of 0.85. The firm’s 50 day moving average is $20.00 and its 200-day moving average is $19.59. Enliven Therapeutics has a 52-week low of $13.30 and a 52-week high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings data on Wednesday, August 13th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.04. Equities analysts expect that Enliven Therapeutics will post -1.95 earnings per share for the current fiscal year.

Insider Activity at Enliven Therapeutics

In other news, CFO Benjamin Hohl sold 3,250 shares of the firm’s stock in a transaction that occurred on Monday, September 29th. The shares were sold at an average price of $20.40, for a total transaction of $66,300.00. Following the completion of the sale, the chief financial officer owned 23,000 shares of the company’s stock, valued at approximately $469,200. This trade represents a 12.38% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Anish Patel sold 6,667 shares of the firm’s stock in a transaction that occurred on Tuesday, October 7th. The stock was sold at an average price of $20.10, for a total transaction of $134,006.70. Following the sale, the chief operating officer directly owned 276,641 shares of the company’s stock, valued at $5,560,484.10. The trade was a 2.35% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 90,734 shares of company stock worth $1,829,844 over the last three months. 25.90% of the stock is owned by corporate insiders.

Institutional Trading of Enliven Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Commodore Capital LP grew its position in shares of Enliven Therapeutics by 0.4% during the second quarter. Commodore Capital LP now owns 4,692,809 shares of the company’s stock worth $94,138,000 after buying an additional 17,809 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Enliven Therapeutics by 7.8% in the second quarter. Geode Capital Management LLC now owns 882,753 shares of the company’s stock worth $17,711,000 after purchasing an additional 63,580 shares during the period. TCG Crossover Management LLC acquired a new position in Enliven Therapeutics in the second quarter worth $9,990,000. Duquesne Family Office LLC acquired a new position in Enliven Therapeutics in the second quarter worth $9,288,000. Finally, Franklin Resources Inc. boosted its holdings in Enliven Therapeutics by 2,029.3% in the second quarter. Franklin Resources Inc. now owns 430,240 shares of the company’s stock worth $8,631,000 after purchasing an additional 410,034 shares during the period. Institutional investors and hedge funds own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.